로딩 중…
지수 로딩 중…
Syndax Pharmaceuticals, Inc.
SNDX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$19.24+1.00%
2026-08-03
Financials
Valuation Metrics
Syndax Pharmaceuticals, Inc.'s Market Cap is $1.70B. At end of 2025 it was $1.82B. Ranked #2168 of 3,112 in US market (top 70%), #850 of 1,445 on NASDAQ (top 59%), #152 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.70B | US#2,168/3,112 Sec#152/269 |
| Revenue | $217M | US#2,659/3,112 Sec#111/269 |
| Net Income | $-243M | US—/3,112 Sec—/269 |
| Total Assets | $473M | US#2,761/3,112 Sec#162/269 |
| Net Assets | $42M | US#2,950/3,112 Sec#245/269 |
| Value | ||
| P/B | 40.96x | US#2,916/3,112 Sec#247/269 |
| P/S | 7.85x | US#2,559/3,112 Sec#110/269 |
| FCF Yield | -16.33% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROA | -51.46% | US#2,970/3,112 Sec#219/269 |
| Op. Margin | -102.93% | US#2,825/3,112 Sec#124/269 |
| Revenue Growth | 223.64% | US#67/3,112 Sec#21/269 |
| Financial Health | ||
| Debt Ratio | 1035.62% | US#2,779/3,112 Sec#245/269 |
| Total Debt | $345M | US#1,986/3,112 Sec#69/269 |
| FCF | $-278M | US#2,774/3,112 Sec#233/269 |
| Cash | $131M | US#2,036/3,112 Sec#156/269 |
| Current Ratio | 5.47x | US#436/3,112 Sec#136/269 |
| Performance | ||
| 1Y Return | 92.79% | US#388/3,112 Sec#89/269 |
| 1M Return | -11.82% | US#2,689/3,112 Sec#186/269 |
| From 52W High | -24.81% | US#1,934/3,112 Sec#137/269 |
| 1Y MDD | -32.56% | US#1,552/3,112 Sec#100/269 |
| Trading | ||
| Volume | 1,569,075 shares | US#1,087/3,112 Sec#99/269 |
| Trading Value | $30M | US#1,728/3,112 Sec#117/269 |
| Per Share | ||
| EPS | $-3.30 | US—/3,112 Sec—/269 |
| BPS | $0.75 | US#2,657/3,112 Sec#211/269 |